177 related articles for article (PubMed ID: 35884555)
41. High mobility group AT-hook 2 and c-MYC as potential prognostic factors in pancreatic ductal adenocarcinoma.
Li K; Yang J; Chen J; Shi Y; Zhang Z; Chen W
Oncol Lett; 2020 Feb; 19(2):1584-1592. PubMed ID: 31966084
[TBL] [Abstract][Full Text] [Related]
42. Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas.
Zhang K; Yao H; Yang Z; Li D; Yang L; Zou Q; Yuan Y; Miao X
Clin Transl Oncol; 2016 Apr; 18(4):352-9. PubMed ID: 26887611
[TBL] [Abstract][Full Text] [Related]
43. Comprehensive histological evaluation with clinical analysis of venous invasion in pancreatic ductal adenocarcinoma: From histology to clinical implications.
Lee SJ; Sung YN; Kim SJ; Shin S; Cho H; Hruban RH; Hong SM
Pancreatology; 2020 Oct; 20(7):1486-1494. PubMed ID: 32948429
[TBL] [Abstract][Full Text] [Related]
44. SURVIVIN POSITIVITY AND PROGNOSTIC FACTORS IN PAPILLARY THYROID CARCINOMAS.
Keskin EU; Taştekin E; Can N; Mut AN; Celik M; Bulbul BY; Puyan FO; Ozyilmaz F; Guldiken S; Ayturk S; Sezer A; Üstün F
Acta Endocrinol (Buchar); 2021; 17(4):455-461. PubMed ID: 35747869
[TBL] [Abstract][Full Text] [Related]
45. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
46. Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma.
Wang X; Zhang CS; Dong XY; Hu Y; Duan BJ; Bai J; Wu YY; Fan L; Liao XH; Kang Y; Zhang P; Li MY; Xu J; Mao ZJ; Liu HT; Zhang XL; Tian LF; Li EX
World J Gastrointest Oncol; 2022 Jul; 14(7):1252-1264. PubMed ID: 36051096
[TBL] [Abstract][Full Text] [Related]
47. Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma.
Janky R; Binda MM; Allemeersch J; Van den Broeck A; Govaere O; Swinnen JV; Roskams T; Aerts S; Topal B
BMC Cancer; 2016 Aug; 16():632. PubMed ID: 27520560
[TBL] [Abstract][Full Text] [Related]
48. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
Nishiwada S; Sho M; Banwait JK; Yamamura K; Akahori T; Nakamura K; Baba H; Goel A
Gastroenterology; 2020 Aug; 159(2):562-574. PubMed ID: 32376411
[TBL] [Abstract][Full Text] [Related]
49. Clinical Outcome and Prognostic Factors of Pancreatic Adenosquamous Carcinoma Compared to Ductal Adenocarcinoma-Results from the German Cancer Registry Group.
Braun R; Klinkhammer-Schalke M; Zeissig SR; Kleihus van Tol K; Bolm L; Honselmann KC; Petrova E; Lapshyn H; Deichmann S; Abdalla TSA; Heckelmann B; Bronsert P; Zemskov S; Hummel R; Keck T; Wellner UF
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010939
[TBL] [Abstract][Full Text] [Related]
50. WT1-associated protein is a novel prognostic factor in pancreatic ductal adenocarcinoma.
Li BQ; Huang S; Shao QQ; Sun J; Zhou L; You L; Zhang TP; Liao Q; Guo JC; Zhao YP
Oncol Lett; 2017 Apr; 13(4):2531-2538. PubMed ID: 28454430
[TBL] [Abstract][Full Text] [Related]
51. Clinicopathological significance of Necl-4 expression in pancreatic ductal adenocarcinoma.
Kawanishi A; Hirabayashi K; Yamada M; Takanashi Y; Hadano A; Kawaguchi Y; Nakagohri T; Nakamura N; Mine T
J Clin Pathol; 2017 Jul; 70(7):619-624. PubMed ID: 27980052
[TBL] [Abstract][Full Text] [Related]
52. Clinical impact of circulating LAPTM4B-35 in pancreatic ductal adenocarcinoma.
Yang Z; Senninger N; Flammang I; Ye Q; Dhayat SA
J Cancer Res Clin Oncol; 2019 May; 145(5):1165-1178. PubMed ID: 30778748
[TBL] [Abstract][Full Text] [Related]
53. A novel long non-coding RNA ENST00000480739 suppresses tumour cell invasion by regulating OS-9 and HIF-1α in pancreatic ductal adenocarcinoma.
Sun YW; Chen YF; Li J; Huo YM; Liu DJ; Hua R; Zhang JF; Liu W; Yang JY; Fu XL; Yan T; Hong J; Cao H
Br J Cancer; 2014 Nov; 111(11):2131-41. PubMed ID: 25314054
[TBL] [Abstract][Full Text] [Related]
54. Coexpression of EGFR and CXCR4 predicts poor prognosis in resected pancreatic ductal adenocarcinoma.
Wu H; Zhu L; Zhang H; Shi X; Zhang L; Wang W; Xue H; Liang Z
PLoS One; 2015; 10(2):e0116803. PubMed ID: 25679210
[TBL] [Abstract][Full Text] [Related]
55. [Expression and clinical significance of Tspan 1 and Integrin α6 in human pancreatic ductal adenocarcinoma].
Shi G; Dong M; Sheng W; Zhou J; Yu D; Sun W
Zhonghua Wai Ke Za Zhi; 2014 Oct; 52(10):781-6. PubMed ID: 25573220
[TBL] [Abstract][Full Text] [Related]
56. Prognostic significance of high mobility group A2 (HMGA2) in pancreatic ductal adenocarcinoma: malignant functions of cytoplasmic HMGA2 expression.
Gundlach JP; Hauser C; Schlegel FM; Willms A; Halske C; Röder C; Krüger S; Röcken C; Becker T; Kalthoff H; Trauzold A
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3313-3324. PubMed ID: 34302528
[TBL] [Abstract][Full Text] [Related]
57. Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma.
Yao H; Yang Z; Liu Z; Miao X; Yang L; Li D; Zou Q; Yuan Y
Cancer Biomark; 2016; 17(4):397-404. PubMed ID: 27689616
[TBL] [Abstract][Full Text] [Related]
58. High GFPT1 expression predicts unfavorable outcomes in patients with resectable pancreatic ductal adenocarcinoma.
Gong Y; Qian Y; Luo G; Liu Y; Wang R; Deng S; Cheng H; Jin K; Ni Q; Yu X; Wu W; Liu C
World J Surg Oncol; 2021 Jan; 19(1):35. PubMed ID: 33517899
[TBL] [Abstract][Full Text] [Related]
59. Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study.
Guo JC; Zhang P; Zhou L; You L; Liu QF; Zhang ZG; Sun B; Liang ZY; Lu J; Yuan D; Tan AD; Sun J; Liao Q; Dai MH; Xiao GG; Li S; Zhang TP
EBioMedicine; 2020 May; 55():102767. PubMed ID: 32361251
[TBL] [Abstract][Full Text] [Related]
60. Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and metastasis in mice tumor models.
Shinkai K; Nakano K; Cui L; Mizuuchi Y; Onishi H; Oda Y; Obika S; Tanaka M; Katano M
Int J Cancer; 2016 Jul; 139(2):433-45. PubMed ID: 26939718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
